Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access
This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.
A Partnership to Expand Access to Lifesaving Testing and Treatment for Hepatitis C
Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.
Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination
This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.
New York Increases Access to Hepatitis C Treatment for Medicaid Patients
The National Viral Hepatitis Roundtable (NVHR), the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI), and the Treatment Action Group (TAG) today applauded New York State (NYS) Medicaid for removing the requirement that new patients receive prior authorization approval for hepatitis C treatment.
Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)
On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.
African Declaration to Eliminate Hepatitis C and Improve the Health of People Who Use Drugs
A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.
Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa
An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.
Good COPs or Bad COPs: Promoting Interventions for Coinfections and AIDS in 2020 PEPFAR Country Operational Plans (COPs)
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Activist Guide to Hepatitis C Virus Diagnostics
The purpose of this new publication is to provide information for you and your community. The Activist Guide aims to provide a deeper focus on diagnosis with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.
Viekira XR and Technivie Fact Sheet
Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination…